Over the years, various recombinant TRAIL variants have been engineered to enhance the stability and pharmacologic potency of the cytokine but, much to our surprise, truly cancer-targeted variants have not yet been tested in clinical trials. This evidence concerns the gene TNFSF10 and cancer.